MedTrace Logo

Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers

NCT00343044 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2015-05-15

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the clinical safety and toxicity of intravenous bevacizumab (Days 1 and 15 of a 28 day cycle) in combination with weekly topotecan (Days 1, 8, 15 of a 28 day cycle) in patients with platinum resistant recurrent ovarian, fallopian tube and primary peritoneal cancer.

Conditions

Interventions

DRUG

Topotecan

Topotecan administered days 1, 8, and 15 of each 28 day cycle. Dose was 4 mg/m2 administered IV.

DRUG

Bevacizumab

bevacizumab administered IV 10 mg/kg, days 1 and 15 of 28 day cycle.

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • Genentech, Inc.

    collaborator INDUSTRY

  • Benaroya Research Institute

    lead OTHER

Principal Investigators

  • Kathryn McGonigle, MD · Virginia Mason Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2010-01-31
Completion
2011-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00343044 on ClinicalTrials.gov